This inventor holds 7 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: University of Pennsylvania, Vanderbilt University. Active years: 2016-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Richmond Hill, GA (US) (2022)
- Drexel Hill, PA (US) (2016 - 2023)
Company Filing History:
7 out of 2,659 
5 out of 1,221 
Years Active: 2016-2023
Title: Adegoke O Adeniji: Innovator in Cancer Treatment
Introduction
Adegoke O Adeniji is a prominent inventor based in Drexel Hill, Pennsylvania, known for his significant contributions to cancer treatment research. With a total of seven patents to his name, Adeniji has focused on developing innovative therapies for castrate-resistant prostate cancer.
Latest Patents
Adegoke O Adeniji's latest patents include groundbreaking work on indomethacin analogs aimed at treating castrate-resistant prostate cancer. These compositions are designed to inhibit the biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. The indomethacin derivatives developed by Adeniji are specific inhibitors of AKR1C3, providing methods for producing these derivatives that lack cyclooxygenase inhibitory activity while retaining AKR1C3 inhibitory activity. Additionally, he has patented 2-beta-naphthyl-acetic acid analogs as selective AKR1C3 inhibitors, which include (R)-naproxen analogs. These compounds are intended for treating various forms of cancer, including prostate cancer and castration-resistant prostate cancer.
Career Highlights
Adegoke O Adeniji has had a distinguished career, working at prestigious institutions such as the University of Pennsylvania and Vanderbilt University. His research has significantly advanced the understanding and treatment of prostate cancer, making him a key figure in the field of oncology.
Collaborations
Throughout his career, Adeniji has collaborated with notable colleagues, including Trevor M Penning and Lawrence J Marnett. These partnerships have further enriched his research and contributed to the development of effective cancer therapies.
Conclusion
Adegoke O Adeniji's innovative work in cancer treatment, particularly in developing AKR1C3 inhibitors, showcases his dedication to improving patient outcomes. His contributions to the field of oncology are invaluable and continue to inspire future research in cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile